🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for HER2 Positive OR TROP2 Positive Non-Small Cell Lung Cancer

Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas NCT04620187Phase 213 sites📍 Atlanta📍 Chicago📍 Boston Dana-Farber Cancer Institute · Tests: Ado-trastuzumab (T) emtansine (T-DM1), Standard of Care Radiotherapy, Standard of Care Chemotherapy Evaluation of [68Ga]Ga-NOTA-anti-HER2-sdAb PET/CT for Predicting Pathological Complete Response After Neoadjuvant Chemotherapy in HER2 Positive Early Breast Cancer NCT07593976Phase 21 site📍 Rouen Centre Henri Becquerel · Tests: [68Ga]Ga-NOTA-anti-HER2-sdAb Positron Emission Tomography SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer NCT06340230Phase 21 site📍 Shenyang Shengjing Hospital · Tests: SHR-A1811 Injection + Adebrelimab Injection, SHR-A1811 Injection + Adebrelimab Injection, SHR-A1811 Injection Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer NCT04090567Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Cediranib, Ceralasertib, Olaparib ABCSG 61 / TEODOR : Neoadjuvant TrEatment Optimization Driven by Circulating Tumor DNA and endOcrine Responsiveness NCT07084558NA14 sites📍 Vienna📍 Baden📍 Dornbirn Austrian Breast & Colorectal Cancer Study Group · Tests: blood sample for Signatera (TM) test, biopsy for Ki-67 assessment, FFPE tumor sample for Signatera (TM) test (archived) First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT) NCT05749900Phase 1, Phase 21 site📍 Seoul Yonsei University · Tests: Trastuzumab+Nivolumab+Gemcitabine+Cisplatin A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer NCT06678269Phase 17 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: Abemaciclib, Radiation Therapy Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks NCT05212454Phase 31 site📍 Hanzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: Capecitabine A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors NCT07318805Phase 113 sites📍 Duarte📍 Grand Rapids📍 Long Island City Pfizer · Tests: PF-08032562, Fulvestrant, Cetuximab, Fluorouracil, Oxaliplatin Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer NCT06179303Phase 23 sites📍 St Louis📍 Chapel Hill📍 Seattle University of Washington · Tests: Abemaciclib, Anastrozole, Biospecimen Collection, Computed Tomography, Diagnostic Imaging Testing DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs NCT06176261Phase 23 sites📍 Miami📍 Boston📍 Durham Nancy Lin, MD · Tests: Datopotamab Deruxtecan First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) NCT06730373Phase 220 sites📍 Zhengzhou📍 Binzhou📍 Dongying Qilu Hospital of Shandong University · Tests: Disitamab Vedotin, Sintilimab, S-1, Trastuzumab, Oxaliplatin IKS014 in Advanced Solid Tumors That Express HER2 NCT05872295Phase 113 sites📍 Newport Beach📍 Boston📍 Nashville Iksuda Therapeutics Ltd. · Tests: IKS014 EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC NCT07617805Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: EGFR/HER2 Dual-Target CAR-NK Cells, Fludarabine, Cyclophosphamide Short Course Radiotherapy With Sequential Disitamab Vedotin Combined With S-1 and Sintilimab as Whole Course Neoadjuvant Therapy for HER2 Expressed Locally Progressive Gastric Cancer NCT06487429Phase 21 site📍 Wuhan Union Hospital, Tongji Medical College, Huazhong University… · Tests: Short range radiotherapy with sequential Disitamab Vedotin combined with S-1 and xindilizumab Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors NCT06658951NA1 site📍 Zhengzhou UTC Therapeutics Inc. · Tests: Anti-HER2 CAR-T cells A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer NCT07678957Phase 21 site📍 Beijing Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-M07D1, DS-8201 Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer NCT05950945Phase 388 sites📍 Miami Beach📍 Tampa📍 Boston Daiichi Sankyo · Tests: Trastuzumab Deruxtecan A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer NCT07347600n/a32 sites📍 Xiamen📍 Lanzhou📍 Shijiazhuang Hoffmann-La Roche · Tests: Inavolisib, Palbociclib, Fulvestrant A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy NCT07071337Phase 32 sites📍 Beijing📍 Guangzhou Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Tests: SKB264, Nab-paclitaxel, Paclitaxel, Capecitabine Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC NCT07797218Phase 31 site📍 Shanghai Shanghai Jiao Tong University School of Medicine · Tests: Docetaxel, Pyrotinib, Trastuzumab (Herceptin), Pertuzumab KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy NCT05427383Phase 2, Phase 31 site📍 Beijing Shanghai JMT-Bio Inc. · Tests: KN026/Placbo Injection, Paclitaxel Injection, Docetaxel Injection, Irinotecan Injection Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer NCT05306041Phase 262 sites📍 Essen📍 Augsburg📍 Berlin GBG Forschungs GmbH · Tests: Inavolisib, PHESGO, Endocrine therapy A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer NCT04985266Phase 249 sites📍 Angers📍 Annecy📍 Avignon Royal Marsden NHS Foundation Trust · Tests: Palbociclib 125Mg Tab, Fulvestrant injection, Tamoxifen, Letrozole, Exemestane Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC. NCT06705127Phase 21 site📍 Hangzhou First Affiliated Hospital of Zhejiang University · Tests: TORIPALIMAB INJECTION(JS001 ), Stereotactic Body Radiation Therapy (SBRT) Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer NCT05524584Phase 21 site📍 Orange University of California, Irvine · Tests: Fulvestrant, Anastrozole, Abemaciclib Pilot Study on the Clinical Efficacy of Focused Ultrasound-Mediated Targeted Drug Delivery System Combined With Neoadjuvant Therapy for HER2-Positive Breast Cancer NCT07616440NA1 site📍 Hangzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: Focused Ultrasound-Mediated Targeted Drug Delivery Combined with Neoadjuvant Therapy HER2+ CNS Surveillance NCT07748598NA1 site📍 Liverpool The Clatterbridge Cancer Centre NHS Foundation Trust · Tests: Intervention for Arm 2: Brain MRI Surveillance A Study of the TheraBionic P1 Device in Breast Cancer NCT07218432NA8 sites📍 Clarkston📍 Detroit📍 Farmington Hills Barbara Ann Karmanos Cancer Institute · Tests: TheraBionic P1 Device Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive Patients NCT06722599n/a1 site📍 Beijing Shu Wang
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy